MindMaze Therapeutics Holding SA has officially completed its business combination with NeuroX Group SA, creating a new entity dedicated to advancing digital treatments for neurological disorders. The merger, finalized on December 15, 2025, brings together the expertise of both companies under the MindMaze name, enhancing their capabilities in precision neurotherapeutics.
The merger follows a definitive business combination agreement signed in October 2025, which received shareholder approval at an extraordinary general meeting in November. The newly established MindMaze Therapeutics is now positioned to redefine neurological care by integrating pharmacological treatments, advanced devices, and an AI-powered platform aimed at improving patient outcomes.
“Neurological diseases are one of the leading causes of disability globally,” stated Olaf Blanke, a board member and professor at the Swiss Federal Institute of Technology (EPFL). He emphasized the urgency for effective solutions as aging populations contribute to an increasing prevalence of these conditions. With an estimated 1 in 6 individuals likely to develop a neurological disorder, the demand for innovative and scalable treatments is more pressing than ever.
The company aims to bridge the gap in neuro-rehabilitation, where traditional healthcare systems often fail to provide adequate therapy. “MindMaze Therapeutics seeks to address this gap by providing clinically proven neurotherapeutics to support recovery from hospital to rehabilitation centers and home,” Blanke added.
Walid Hanna, Chairman of the Board of Directors of MindMaze Therapeutics, remarked, “Today begins a new chapter for MindMaze Therapeutics. The company is founded on clinically validated innovation, driven by a mission to transform neurological care.” He noted that the integration with Relief Therapeutics enhances their drug-digital strategy and expands development opportunities in the field of neurological health.
The merger involved a share exchange where former shareholders of NeuroX received 140,000,000 newly issued ordinary shares of MindMaze. These shares will be listed and traded on the SIX Swiss Exchange under the new ticker symbol MMTX. Following the transaction, the total number of outstanding shares of MindMaze Therapeutics reached 152,602,044, excluding treasury shares.
MindMaze Therapeutics, now a commercial-stage company, focuses on developing and commercializing innovative digital treatments for neurological diseases. Its advanced technology platform combines software, sensors, and telehealth solutions, which are utilized across clinics and home settings worldwide. The company’s clinically validated neurotherapeutics have shown promising outcomes for conditions such as stroke and Parkinson’s disease, and it is expanding its research into other neurological indications, including multiple sclerosis and Alzheimer’s disease.
In addition, MindMaze Therapeutics will also manage Relief’s existing portfolio of biopharmaceutical assets, which concentrate on rare dermatological, metabolic, and respiratory diseases. The company is listed on the SIX Swiss Exchange and quoted on the OTCQB under the ticker symbols RLFTF and RLFTY.
For additional information about MindMaze Therapeutics and its mission to innovate neurological care, visit their website at www.mindmazetherapeutics.com.
This merger marks a significant step forward in the landscape of neurological treatment, aiming for a comprehensive approach that integrates both digital and pharmacological therapies to better serve patients globally.
